TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ERY-TAB

ERYTHROMYCIN
Infectious Disease Approved 1982-03-29
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
1
Indication
--
Phase 3 Trials
43
Years on Market

Details

Status
Prescription
First Approved
1982-03-29
Routes
ORAL
Dosage Forms
TABLET, DELAYED RELEASE

Companies

PHARMOBEDIENT
Active Ingredient: ERYTHROMYCIN

ERY-TAB Approval History

Loading approval history...

What ERY-TAB Treats

5 indications

ERY-TAB is approved for 5 conditions since its original approval in 1982. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Upper Respiratory Tract Infection
  • Lower Respiratory Tract Infection
  • Listeriosis
  • Respiratory Tract Infection
  • Skin Infection
Source: FDA Label

Drugs Similar to ERY-TAB

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACHROMYCIN V
TETRACYCLINE HYDROCHLORIDE
2 shared
AVET
Shared indications:
Upper Respiratory Tract InfectionLower Respiratory Tract Infection
ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN LACTOBIONATE
2 shared
GLAND
Shared indications:
Upper Respiratory Tract InfectionLower Respiratory Tract Infection
FIRVANQ KIT
VANCOMYCIN HYDROCHLORIDE
2 shared
AZURITY
Shared indications:
Lower Respiratory Tract InfectionSkin Infection
SUMYCIN
TETRACYCLINE HYDROCHLORIDE
2 shared
STRIDES PHARMA INTL
Shared indications:
Upper Respiratory Tract InfectionLower Respiratory Tract Infection
VANCOCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE
2 shared
ANI PHARMS
Shared indications:
Lower Respiratory Tract InfectionSkin Infection
VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE
2 shared
SAGENT PHARMS
Shared indications:
Lower Respiratory Tract InfectionSkin Infection
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER
VANCOMYCIN HYDROCHLORIDE
2 shared
Baxter
Shared indications:
Lower Respiratory Tract InfectionSkin Infection
ACTICLATE
DOXYCYCLINE HYCLATE
1 shared
CHARTWELL RX
Shared indications:
Respiratory Tract Infection
AMOXICILLIN PEDIATRIC
AMOXICILLIN
1 shared
Teva
Shared indications:
Lower Respiratory Tract Infection
AMPICILLIN SODIUM
AMPICILLIN SODIUM
1 shared
SAGENT PHARMS INC
Shared indications:
Respiratory Tract Infection
ARIKAYCE KIT
AMIKACIN SULFATE
1 shared
INSMED INC
Shared indications:
Respiratory Tract Infection
AUGMENTIN '125'
AMOXICILLIN
1 shared
US ANTIBIOTICS
Shared indications:
Lower Respiratory Tract Infection
AUGMENTIN '250'
AMOXICILLIN
1 shared
US ANTIBIOTICS
Shared indications:
Lower Respiratory Tract Infection
AUGMENTIN '875'
AMOXICILLIN
1 shared
US ANTIBIOTICS
Shared indications:
Lower Respiratory Tract Infection
AUGMENTIN XR
AMOXICILLIN
1 shared
US ANTIBIOTICS
Shared indications:
Lower Respiratory Tract Infection
AZACTAM
AZTREONAM
1 shared
Bristol-Myers Squibb
Shared indications:
Lower Respiratory Tract Infection
AZTREONAM
AZTREONAM
1 shared
Pfizer
Shared indications:
Lower Respiratory Tract Infection
BICILLIN C-R 900/300
PENICILLIN G BENZATHINE
1 shared
KING PHARMS LLC
Shared indications:
Upper Respiratory Tract Infection
CEFOTAN
CEFOTETAN DISODIUM
1 shared
PAI HOLDINGS PHARM
Shared indications:
Lower Respiratory Tract Infection
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER
CEFOXITIN SODIUM
1 shared
B BRAUN
Shared indications:
Lower Respiratory Tract Infection
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ERY-TAB FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ERY-TAB ® and other antibacterial drugs, ERY-TAB ® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ERY-TAB ® tablets are indicated in the treatment of infections caused by ...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: ANDA062298 → Label: DailyMed → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.